Pangaea OncologyXMAD:PANG 67 ROA % is -12.35% as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 67/100 and a GF Value™ of €2.14 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 65.42% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pangaea Oncology's annualizedNet Income for the quarter that ended in Dec. 2025 was €-3.81 Mil.
Pangaea Oncology's average Total Assets over the quarter that ended in Dec. 2025 was €30.84 Mil. Therefore, Pangaea Oncology's annualized ROA % for the quarter that ended in Dec. 2025 was -12.35%.
The historical rank and industry rank for Pangaea Oncology's ROA % or its related term are showing as below:
XMAD:PANG'
s ROA % Range Over the Past 10 Years
Min: -26.05 Med: -9.64 Max: -3.39
Current: -11.47
During the past 13 years, Pangaea Oncology's highest ROA % was -3.39%. The lowest was -26.05%. And the median was -9.64%.
XMAD:PANG's ROA % is ranked worse than 65.42% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.11
vs XMAD:PANG: -11.47
Pangaea Oncology (XMAD:PANG) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Pangaea Oncology ROA % Related Terms
Pangaea Oncology ROA % Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Pangaea Oncology's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's ROA % distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Pangaea Oncology (XMAD:PANG) has a ROA % of -12.35% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pangaea Oncology and its competitors. According to the industry distribution chart, Pangaea Oncology ranks #140 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 65.4%.
Is Pangaea Oncology's ROA % too high?
Pangaea Oncology's current ROA % is -12.35%. Based on the distribution chart, Pangaea Oncology ranks #140 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Pangaea Oncology has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #140 out of 214 companies for ROA %. This places Pangaea Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pangaea Oncology and its competitors. Pangaea Oncology's current ROA % is -12.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.14, compared to a current price of €1.51 — trading 29.4% below its estimated fair value. The current ROA % is -12.35%. Pangaea Oncology's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current ROA % is -12.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.4% below its estimated GF Value™ of €2.14.
GuruFocus considers Pangaea Oncology to be Modestly Undervalued.
Key valuation signals for XMAD:PANG:
ROA %: -12.35%
GF Value™: €2.14 vs. price of €1.51 (29.4% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
67GF Score
Get the complete analysis for XMAD:PANG
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
